New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CAT;IQNT;GRMN;JCP;JNJ;KRC;NKTR;STRA;VRTX;VNO;BMY;PBR;HES From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
July 31, 2015
10:02 EDTKRCOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:27 EDTJNJJohnson & Johnson drug business likely to remain resilient, says Wells Fargo
Subscribe for More Information
06:28 EDTKRCKilroy Realty downgraded to Underperform from Neutral at Credit Suisse
Subscribe for More Information
July 30, 2015
21:11 EDTKRCKilroy Realty downgraded to Underperform from Neutral at Credit Suisse
18:52 EDTPBRVantage Drilling responds to media reports
Subscribe for More Information
13:45 EDTKRCKilroy Realty sees year-end occupancy approximately 94.5%
Subscribe for More Information
13:24 EDTKRCKilroy Realty raises FY15 FFO view to $3.30-$3.40 from $3.25-$3.39
Subscribe for More Information
13:21 EDTKRCKilroy Realty sees FY15 FFO $3.30-$3.40, consensus $3.33
Sees FY15 CapEx weighted to back half of year. Sees year-end occupancy rate mid 90's range. Guidance from Q2 earnings conference call.
13:16 EDTKRCKilroy Realty says in discussions for significant dispositions
Subscribe for More Information
10:00 EDTHESOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
10:00 EDTGRMNOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Altria Group (MO) downgraded to Outperform from Buy at CLSA... Baxter (BAX) downgraded to Market Perform from Outperform at Leerink... Changyou.com (CYOU) downgraded to Hold from Buy at Summit Research... Depomed (DEPO) downgraded to Neutral from Buy at Janney Capital... Euronet (EEFT) downgraded to Neutral from Buy at Monness Crespi... Foundation Medicine (FMI) downgraded to Market Perform at JMP Securities... Garmin (GRMN) downgraded to Underweight from Neutral at JPMorgan... Golden Star Resources (GSS) downgraded to Hold at Canaccord... Grainger (GWW) downgraded on negative catalysts at RBC Capital... Henry Schein (HSIC) downgraded to Hold from Buy at Evercore ISI... LINN Energy (LINE) downgraded to Market Perform from Outperform at Raymond James... LifeLock (LOCK) downgraded to Neutral from Buy at BofA/Merrill... LinnCo (LNCO) downgraded to Market Perform from Outperform at Raymond James... Manitowoc (MTW) downgraded to Hold from Buy at BB&T... PACCAR (PCAR) downgraded to Equal Weight on peak cycle concerns at Morgan Stanley... PG&E (PCG) downgraded to Neutral from Outperform at Credit Suisse... Pacer (PACR) downgraded to Equal Weight from Overweight at Morgan Stanley... Penn Virginia (PVA) downgraded to Sector Perform from Outperform at Scotia... Shutterfly (SFLY) downgraded to Market Perform at Raymond James... Terex (TEX) downgraded to Hold from Buy at BB&T... Total System (TSS) downgraded to Neutral at Baird... Whiting Petroleum (WLL) downgraded to Equal Weight from Overweight at Stephens... Whole Foods (WFM) downgraded to Equal Weight from Overweight at Morgan Stanley.
08:18 EDTHESHess Corp. upgraded to Buy from Hold at Societe Generale
Subscribe for More Information
07:31 EDTGRMNGarmin to open brick-and-mortar stores in greater Miami area
Subscribe for More Information
06:30 EDTGRMNGarmin downgraded to Underweight from Neutral at JPMorgan
Subscribe for More Information
July 29, 2015
19:08 EDTBMYBristol-Myers enters immuno-oncology collaboration with Kyowa Hakko Kirin
Kyowa Hakko Kirin and Bristol-Myers Squibb announced that the companies have entered into a clinical trial collaboration agreement to conduct a Phase 1/2 combination study with mogamulizumab, an anti-CCR4 antibody and Opdivo, a PD-1 immune checkpoint inhibitor. The study, which will be conducted in the U.S., will focus on evaluating the safety, tolerability and anti-tumor activity of combining mogamulizumab and Opdivo as a potential treatment option for patients with advanced or metastatic solid tumors. Prior to this agreement, Kyowa Hakko Kirin, Bristol-Myers Squibb and Ono Pharmaceutical entered into a clinical trial collaboration agreement to study the combination of mogamulizumab and Opdivo in Japan. Mogamulizumab and Opdivo are part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system.
17:44 EDTKRCKilroy Realty reports Q2 FFO 82c, consensus 76c
Reports Q2 revenue $146.23M, consensus $134.66M.
16:10 EDTVRTXVertex raises 2015 KALYDECO sales outlook to $575M-$590M
Subscribe for More Information
16:09 EDTVRTXVertex reports Q2 EPS (54c), consensus (58c)
Reports Q2 revenue $166.1M, consensus $149.7M. Reports KALYDECO product revenue $154.9M vs. $113.1M last year.
15:59 EDTVRTXNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Facebook (FB), consensus 47c... MetLife (MET), consensus $1.48... Williams (WMB), consensus 24c... Vertex (VRTX), consensus (58c)... O'Reilly Automotive (ORLY), consensus $2.26... NXP Semiconductors (NXPI), consensus $1.37... Marriott (MAR), consensus 81c... Fiserv (FISV), consensus 94c... Western Digital (WDC), consensus $1.45... SBA Communications (SBAC), consensus 9c... Whole Foods (WFM), consensus 45c... Lincoln National (LNC), consensus $1.53... Lam Research (LRCX), consensus $1.47... ServiceNow (NOW), consensus (2c)... Qorvo (QRVO), consensus $1.06... Hologic (HOLX), consensus 39c.
15:08 EDTVRTXNotable companies reporting after market close
Subscribe for More Information
12:17 EDTJNJMedivation plummets after Cowen highlights slowing Xtandi trends
Subscribe for More Information
11:23 EDTJNJMedivir says Janssen's Alios BIopharma starts Phase I AL-704 trial
Subscribe for More Information
10:50 EDTGRMNGarmin says underlying foundation is 'solid', sees long-term growth in Aircraft
Subscribe for More Information
10:17 EDTHESHess raises 2015 production forecast to 360K-370K boe/d
Hess said during its Q2 earning call that in light of its "strong performance year to date," the company is raising its overall company production forecast for 2015 by 10,000 barrels of oil equivalent per day to a range of 360,000-370,000 barrels of oil equivalent per day, excluding Libya. The company added that is production improvement in Q2 was driven by higher production from the Bakken and Utica shale plays, the joint development area of Malaysia/Thailand and Tubular Bells in the Deepwater Gulf of Mexico. Bakken net production averaged 119,000 barrels of oil equivalent per day in Q2, above its guidance range, and Hess is increasing its FY15 production forecast for the Bakken to a range of 105,000-110,000 barrels of oil equivalent per day, up from previous guidance of 95,000-105,000 barrels of oil equivalent per day.
07:37 EDTHESHess Corp. reports Q2 adjusted EPS (52c), consensus (73c)
Oil and gas production was 391,000 boepd, up 23 percent from 319,000 boepd in the second quarter of 2014. Assets contributing to the volume growth were primarily the Bakken shale play, the Utica shale play, the Joint Development Area of Malaysia/Thailand and the Gulf of Mexico. Asset sales reduced production by 9,000 boepd. Lower realized selling prices reduced adjusted net income by approximately $740 million after-tax compared with the prior-year quarter. In addition, second quarter 2015 results benefitted from higher production, lower cash operating costs and reduced exploration expenses that were partially offset by higher depreciation, depletion, and amortization expense. On an unadjusted basis, the Corporation reported a net loss of $567 million for the second quarter of 2015, including a noncash goodwill impairment charge of $385 million, and net income of $931 million in the prior-year quarter.
07:04 EDTGRMNGarmin sees FY15 pro forma EPS about $2.65, consensus $2.78
Subscribe for More Information
07:03 EDTGRMNGarmin reports Q2 EPS 72c, consensus 80c
Subscribe for More Information
06:31 EDTSTRAStrayer reports total enrollments for summer term up 2% to 37,221
Total enrollments at Strayer University for the summer term 2015 increased 2% to 37,221 students compared to 36,403 students for the summer term 2014. New student enrollments increased by 4%, and continuing student enrollments increased by 2%.
06:31 EDTSTRAStrayer reports Q2 EPS $1.11, consensus 99c
Subscribe for More Information
July 28, 2015
15:21 EDTGRMNNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include MasterCard (MA), consensus 85c... Altria (MO), consensus 71... General Dynamics (GD), consensus $2.06... Anthem (ANTM), consensus $2.75... Praxair (PX), consensus $1.46... Northrop Grumman (NOC), consensus $2.36... McKesson (MCK), consensus $2.91... Eaton (ETN), consensus $1.13... Humana (HUM), consensus $1.63... Hilton (HLT), consensus 23c... International Paper (IP), consensus 92c... Rockwell Automation (ROK), consensus $1.54... Jarden (JAH), consensus 59c... Quintiles (Q), consensus 70c... Tableau Software (DATA), consensus 4c... Garmin (GRMN), consensus 82c... Vantiv (VNTV), consensus 54c... ADT (ADT), consensus 49c.
09:32 EDTCATCaterpillar announces $1.5B accelerated stock repurchase
Subscribe for More Information
09:03 EDTCATCaterpillar to begin design of vocational truck product family in Victoria
Caterpillar announced it will begin independently designing and manufacturing its vocational truck product family at its plant in Victoria, Texas. The plant, which opened in 2012, currently produces hydraulic excavators. The transition process will begin immediately, with production expected to begin in the first half of next year. Caterpillar Victoria will continue to produce excavators, and the addition of the vocational truck production is expected to add around 200 new jobs at the facility.
07:20 EDTVRTX, BMYBrookings Institute to hold a public meeting
Subscribe for More Information
07:05 EDTJNJMacroGenics reports MGD011 advances into clinical development
Subscribe for More Information
July 27, 2015
13:11 EDTCATCaterpillar downgraded to Underperform from Neutral at Tigress Financial
Subscribe for More Information
10:40 EDTJNJLeerink major pharma analyst holds an analyst/industry conference call
Subscribe for More Information
07:01 EDTBMYBristol-Myers, AbbVie say EMA validates for review Empliciti MAA
Bristol-Myers Squibb Company (BMY) and AbbVie (ABBV) announced the European Medicines Agency validated for review the Marketing Authorization Application for Empliciti, an investigational Signaling Lymphocyte Activation Molecule-directed immunostimulatory antibody, for the treatment of multiple myeloma as combination therapy in adult patients who have received one or more prior therapies. The application was granted accelerated assessment by the EMA’s Committee for Medicinal Products for Human Use. Bristol-Myers Squibb and AbbVie are co-developing Empliciti, with Bristol-Myers Squibb solely responsible for commercial activities. Bristol-Myers Squibb has proposed the name Empliciti which, if approved by health authorities, will serve as the trade name for elotuzumab. The MAA is primarily supported by data from two randomized clinical trials, each combining Empliciti with a different standard of care regimen for multiple myeloma. ELOQUENT-2, a Phase 3, randomized, open-label study, evaluated Empliciti in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone. The results of this trial were published in The New England Journal of Medicine on June 2. Additionally, a Phase 2, randomized, open-label study evaluated Empliciti with bortezomib and dexamethasone versus bortezomib and dexamethasone alone. These Phase 2 results were presented in an oral session at the 20th Congress of the European Hematology Association. Empliciti previously obtained orphan drug designation in the European Union. An orphan medicinal product must be intended for the treatment, prevention or diagnosis of a disease that is life threatening and chronically debilitating; the prevalence in the EU must not be more than five in 10,000. The medicine must be of significant benefit to those affected by the condition. If maintained, orphan drug designation allows sponsors to access a number of incentives including protocol assistance and receive market exclusivity for a ten-year period following approval.
July 24, 2015
16:30 EDTCATStocks end week lower as Apple headlines busy week of earnings
Subscribe for More Information
14:08 EDTBMYBristol-Myers confirms FDA approval of hepatitis drug Daklinza
Subscribe for More Information
13:49 EDTBMYFDA approves new treatment for chronic hepatitis C genotype 3
Subscribe for More Information
11:02 EDTBMYBristol-Myers selects Jones Lang LaSalle for facility management
Subscribe for More Information
July 23, 2015
18:21 EDTCAT, BMYOn The Fly: Top stock stories for Thursday
Stocks began the session mixed on the heels of weak earnings reports from both Caterpillar (CAT) and 3M (MMM). The Nasdaq managed to spend most of the day in positive territory but joined the other averages in negative territory by mid-afternoon. Selling picked up momentum towards late afternoon, and by day’s end each of the averages were lower by more than 0.4%, with the Dow losing nearly 0.7%. ECONOMIC EVENTS: In the U.S., initial jobless claims fell to 255,000 in the week ended July 18, below the 278,000 first-time claims that were expected. The Leading Economic Indicators advanced 0.6% in June, exceeding expectations for a 0.3% increase. In Asia, the Shanghai Composite index advanced for a sixth straight session, adding another 2.4%. In Europe, the Greek Parliament voted to accept creditor terms for a new bailout, though a decision on when to reopen Greek financial markets was deferred to next week. COMPANY NEWS: Shares of General Motors (GM) finished the session up 3.96% to $31.50 after reporting earnings per share above analyst expectations. Other notable names rising following earnings reports include SanDisk (SNDK), Under Armour (UA), Southwest (LUV)... Caterpillar, meanwhile, dropped $2.86, or 3.59%, to $76.90 after cutting its yearly guidance during this morning's earnings report, with the company noting a "relatively stagnant" global economy. Also lower following earnings were Comcast (CMCSA, CMCSK), Bristol-Myers Squibb (BMY), Dunkin Brands (DNKN), and Boston Scientific (BSX). MAJOR MOVERS: Among the notable gainers was Cigna (CI), which rose $3.29, or 2.18%, to $154.36 after the Wall Street Journal reported last night that Anthem (ANTM) is nearing a deal to acquire the company for roughly $187, representing a total transaction value of over $48B. Adding to that report, CNBC's David Faber said on Thursday morning that Anthem will announce an agreement Friday to purchase Cigna for $188 per share, at a 45% equity, 55% cash split. Also higher were shares of numerous IT security companies, with FireEye (FEYE) advancing 4.53% and Palo Alto Networks (PANW) adding 2.33% after earnings reports from security firms Fortinet (FTNT) and F5 Networks (FFIV) beat on both top and bottom lines. Fortinet and F5, meanwhile, finished Thursday's session up 10.71% and 7.75% to $46.83 and $127.68, respectively. Among the noteworthy losers following earnings was McDonald's (MCD), which edged down 0.52% to $97.10 after noting that Q2 global comparable sales fell 0.7% for the quarter, including a 2% decline in U.S. same-store sales. Also lower was Hertz (HTZ), which declined 8.53% to $16.45 following a downgrade to Underweight at Morgan Stanley, with the research firm citing increased competition from Uber and similar mobility services. INDEXES: The Dow fell 119.12, or 0.67%, to 17,731.92, the Nasdaq lost 25.36, or 0.49%, to 5,146.41, and the S&P 500 declined 12.00, or 0.57%, to 2,102.15.
17:51 EDTJNJJanssen submits sNDA to update label for Olysio
Subscribe for More Information
12:32 EDTCATOn The Fly: Top stock stories at midday
Subscribe for More Information
11:20 EDTCATCaterpillar sees lower sales and profits in 2H
Subscribe for More Information
11:14 EDTCATCaterpillar sees lower sales in Q3 than Q4
Comments made on Q2 earnings conference call.
09:20 EDTCATCaterpillar demand trends appear negative for Cummins, Terex, says Wells Fargo
Subscribe for More Information
09:13 EDTCATOn The Fly: Pre-market Movers
Subscribe for More Information
07:46 EDTCATCaterpillar announces intention to repurchase $1.5B of common stock in Q3
Subscribe for More Information
07:45 EDTCATCaterpillar cut FY15 revenue guidance due to currency impacts
Subscribe for More Information
07:40 EDTCATCaterpillar Financial reports Q2 revenue $693M, down 6% from 2Q14
Subscribe for More Information
07:34 EDTBMYBristol-Myers raises FY15 adjusted EPS view to $1.70-$1.80 from $1.60-$1.70
Subscribe for More Information
07:34 EDTCATCaterpillar says global economy remains 'relatively stagnant'
Subscribe for More Information
07:33 EDTCATCaterpillar backs FY15 adjusted EPS $5.00, consensus $4.97
Subscribe for More Information
07:32 EDTCATCaterpillar reports Q2 adjusted EPS $1.27, consensus $1.27
Subscribe for More Information
07:31 EDTBMYBristol-Myers reports Q2 EPS 53c, consensus 36c
Subscribe for More Information
07:07 EDTIQNTInteliquent narrows FY15 revenue guidance to $220M-$230M from $215M-$230M
Consensus $222.19M. Narrows FY15 adjusted EBITDA guidance to $77M-$81M from $75M-$81M.
07:06 EDTIQNTInteliquent reports Q2 EPS 29c, consensus 28c
Reports Q2 revenue $52.9M, consensus $56.05M.
06:38 EDTBMYBristol-Myers' two Opdivo applications validated by European Medicines Agency
Subscribe for More Information
July 22, 2015
15:26 EDTBMY, CATNotable companies reporting before tomorrow's open
Subscribe for More Information
14:37 EDTCATCaterpillar technical comments ahead of earnings
The shares are testing the $80 area on the downside ahead of results. On a long-term chart of five years or more, it is clear how important $80 has been as a support. Since 2010 it has only been broken once in any major way. If the news is sufficiently bearish, this support could give way and allow the preceding downtrend to resume. Support levels to watch would be at $78.19 which is the 52-week low, $75.80, and $71.78. If the news is a bullish surprise, the first major test of resistance would come at the 10-month moving average which was last at $87.55. It would take a breakout above the 10-month to turn the short-term trend bullish, with next resistance at $89.62.
14:22 EDTCATCaterpillar July weekly volatility elevated into Q2 and outlook
Subscribe for More Information
13:31 EDTCATEarnings Watch: Wells Fargo says Caterpillar revenue consensus likely too high
Subscribe for More Information
10:37 EDTCATCaterpillar June data suggests consensus revenue view too high, says Wells Fargo
Subscribe for More Information
10:15 EDTJNJThoratec downgraded to Market Perform from Outperform at Northland
Subscribe for More Information
10:01 EDTHES, JCPOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AMC Entertainment (AMC) upgraded to Buy at MKM Partners... Agnico Eagle (AEM) upgraded to Buy from Hold at HSBC... Allegiant Travel (ALGT) upgraded to Outperform from Market Perform at Raymond James... Amazon.com (AMZN) upgraded on positive outlook at JMP Securities... Bank of Ireland (IRE) upgraded to Buy from Neutral at Nomura... Canadian Pacific (CP) upgraded to Buy at Canaccord... Carrizo Oil & Gas (CRZO) upgraded to Outperform from Neutral at Credit Suisse... Concho Resources (CXO) upgraded to Outperform from Neutral at Credit Suisse... Crown Castle (CCI) upgraded to Buy from Neutral at Citi... Exxon Mobil (XOM) upgraded to Conviction Buy from Buy at Goldman... Fidelity & Guaranty Life (FGL) upgraded to Outperform from Neutral at Macquarie... First Interstate (FIBK) upgraded to Buy from Hold at Sandler O'Neill... Hess Corp. (HES) upgraded to Outperform from Neutral at Credit Suisse... Intuitive Surgical (ISRG) upgraded to Buy at Canaccord... J.C. Penney (JCP) upgraded to Buy from Neutral at Buckingham... Murphy Oil (MUR) upgraded to Neutral from Underperform at Credit Suisse... Noble Energy (NBL) upgraded to Outperform at Credit Suisse... Packaging Corp. (PKG) upgraded to Outperform from Market Perform at BMO Capital... Prologis (PLD) upgraded to Outperform from Neutral at Baird... Signature Bank (SBNY) upgraded to Strong Buy from Outperform at Raymond James... Sonic Automotive (SAH) upgraded to Buy from Neutral at BofA/Merrill... Tate & Lyle (TATYY) upgraded to Neutral from Sell at Goldman... Technip (TKPPY) upgraded to Neutral from Sell at Goldman... Union Bankshares (UBSH) upgraded to Buy from Neutral at Compass Point... Yamana Gold (AUY) upgraded to Buy from Hold at HSBC... Yara (YARIY) upgraded to Neutral from Underweight at JPMorgan.
09:34 EDTCATCaterpillar falls, levels to watch
The stock is down 1.7% to $80.83 at time of writing. A big level to watch is the 52-week low at $78.19, which may get retested. Resistance is at $81.78.
09:17 EDTCATCaterpillar reports retail machines sales down 14% in three months end June
Caterpillar reported in a regulatory filing that its total retail machines sales were down 14% on a three month rolling basis in June. For reference, retail sales of machines were down 12% in the period ending in May and were down 11% in the period ending in April. The company reported world Resources Industries sales down 13% in the June period, which was worse than the 8% drop in the May end period. Construction Industries world sales were down 16%, worse than the 14% drop in the May period. Total Energy & Transportation Retail Sales were down 10% in the June end period, which was worse than the 6% decline seen in the May period.
08:38 EDTJCPNRF cuts 2015 retail sales growth forecast to 3.5% from 4.1%
Subscribe for More Information
08:09 EDTJCPJ.C. Penney upgraded to Buy from Neutral at Buckingham
Buckingham upgraded J.C. Penney to Buy and increased its price target to $12 from $9. The firm believes 2H comps could accelerate as initiatives take hold and has increased confidence it the company's ability to hit its 2017 EBITDA target of $1.2B. Buckingham believes FY15 sales comp guidance of 4%-5% is achievable and sees continued gross margin improvement and reduced SG&A levels.
07:54 EDTHESHess Corp. upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
06:59 EDTPBRPortugal joins Petrobras corruption probe, FT reports
A probe into alleged corruption at Petrobras is spreading internationally, with Portugal announced that it will help Brazil in its investigation of the company, the Financial Times reports. Portugal's move comes just after the U.S., Peru, Colombia, Ecuador, and Panama all said that are taking action in the investigation, the report says. Reference Link
July 21, 2015
14:03 EDTBMYBristol-Myers: Data from Phase IIa study support further evaluation of BMS955176
Bristol-Myers Squibb announced additional Phase IIa proof-of-concept data for BMS-955176, a novel investigational agent designed to prevent the maturation of HIV-1. The study findings, which are being presented in a late-breaking oral presentation at the 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, confirmed the antiretroviral activity of BMS-955176 when administered with atazanavir and support further development of the second-generation HIV-1 maturation inhibitor. BMS-955176 is designed to inhibit one of the last steps of the HIV-1 viral lifecycle, resulting in the release of immature non-infectious HIV-1 particles. As part of a multi-part proof-of-concept study, a two-drug combination of BMS-955176 plus atazanavir had a maximum median change in HIV-1 RNA of -2.23 log10 c/mL from baseline through study discharge. The standard of care control of atazanavir 300 mg and ritonavir 100 mg plus tenofovir disoproxyl fumarate 300 mg plus emtricitabine 200 mg in a fixed dose combination had a maximum median change in HIV-1 RNA of -2.39 log10 c/mL from baseline through study discharge. In addition, a lower dose of BMS-955176 plus atazanavir and ritonavir had a similar maximum median change in HIV-1 RNA of -2.20 log10 c/mL. Length of therapy for all treatment groups was 28 days. Study endpoints included change in HIV-1 RNA from baseline to Day 28 and from baseline to the end of the study and safety. Data from Part A and Part B of the Phase IIa proof-of-concept study support the further evaluation of BMS-955176 in novel treatment regimens such as nucleos(t)ide- and booster-sparing regimens to address key unmet needs for HIV-1 treatment-experienced patients. Two Phase IIb studies have started in 2015: a traditional dose-finding study in treatment-naive patients and a second Phase IIb study to evaluate a nucleos(t)ide- and booster-sparing regimen in treatment-experienced patients.
10:34 EDTPBRHelix says in dialogue with clients to find ways to preserve contracted work
Subscribe for More Information
09:02 EDTBMYBristol-Myers Squibb receives FDA breakthrough designation for HIV-1 inhibitor
Bristol-Myers Squibb announced that the FDA has granted Breakthrough Therapy Designation to the investigational compound BMS-663068 when used in combination with other antiretroviral, or ARV, agents for the treatment of HIV-1 infection in heavily treatment-experienced adult patients. BMS-663068 is an oral prodrug of the molecule BMS-626529 and first-in-class HIV-1 attachment inhibitor. The attachment inhibitor is designed to work differently than entry inhibitors, a current class of drugs that targets co-receptors’ activity or fusion after HIV attaches to the CD4+ host cell. BMS-663068 is thought to work at an earlier point in the replication process to prevent the virus’ initial interaction with immune cells entirely, and thus blocks its entry into the cell.
July 20, 2015
12:09 EDTBMYBristol-Myers says Nivolumab BMS approved in EU for SQ NSCLC
Subscribe for More Information
12:08 EDTBMYOn The Fly: Top stock stories at midday
Stocks on Wall Street were slightly higher at midday in the first trading day of a week that will be light on domestic economic data but heavy on earnings reports. Investors will be receiving profit reports from about 25% of the companies on the S&P 500 this week, making this the highest volume earnings week of this season. ECONOMIC EVENTS: In the U.S., no major data was released. In Europe, Greece reopened its banks three weeks after closing as the country worked out another bailout agreement. The country announced it has started the process of paying off its creditors, including the European Central Bank and the International Monetary Fund, with a bridge loan it just received. COMPANY NEWS: Lockheed Martin (LMT) agreed to buy the Sikorsky Aircraft business from United Technologies (UTX) for $9B, noting the price is "effectively reduced" to $7.1B after taking into account tax benefits resulting from the transaction. Shares of Lockheed, which also reported better than expected second quarter results and increased its fiscal year guidance, gained nearly 2% after the Sikorsky announcement and saying it will conduct a strategic review of its government IT infrastructure services business and technical services business... Shares of Morgan Stanley (MS) shares were little changed near noon after the bank reported earnings and revenue, excluding certain adjustments, that topped analysts' consensus forecasts... SunEdison (SUNE) announced a deal to acquire Vivint Solar (VSLR) for approximately $2.2B, payable in a combination of cash, shares of SunEdison common stock and SunEdison convertible notes. In connection with the proposed acquisition of Vivint Solar, SunEdison has entered into a definitive purchase agreement with a subsidiary of TerraForm Power (TERP) which, concurrently with the completion of SunEdison's acquisition of Vivint, will acquire Vivint Solar's rooftop solar portfolio, consisting of 523 MW expected to be installed by year-end 2015, for $922M in cash. Shares of Vivint rose 44% following the announcement, while SunEdison's stock gained 4% and TerraForm dropped 3%. Fellow residential solar installer SolarCity (SCTY), which is backed by Tesla's (TSLA) Elon Musk, rose 7% following the deal in the space. MAJOR MOVERS: Among the notable gainers was Exelixis (EXEL), which rallied 43% after the company reported that a study of cabozantinib in metastatic renal cell carcinoma met its primary endpoint of significant improvement in progression-free survival. The shares were indicated to rise even more in early pre-market trading, but lost some of their gains after Bristol-Myers (BMY) announced that its Opdivo study was stopped early after showing superior overall survival in a Phase 3 study of previously treated patients with advanced or metastatic renal cell carcinoma. Bristol-Myers rose a bit less than 1% to trade near $70 per share after its own announcement. Also higher was PayPal (PYPL), which gained more than 5.5% in its first day of trading after being spun out of eBay (EBAY). Meanwhile, eBay shares rose over 2%. Cal-Maine Foods (CALM) dropped 8% after posting lower than expected sales and profits in its fourth quarter and warning that while it should have an adequate supply of its primary feed ingredients, the company expects that prices will be "volatile" in the year ahead. Also lower were shares of several gold miners, including Barrick Gold (ABX) and Newmont Mining (NEM), which each fell about 11%, as gold prices declined about 2% near midday. INDEXES: Near midday, the Dow was up 31.66, or 0.18%, to 18,118.11, the Nasdaq was up 9.81, or 0.19%, to 5,219.96, and the S&P 500 was up 2.82, or 0.13%, to 2,129.46.
08:28 EDTBMYExelixis off highs, but still up 34% after Bristol-Myers data
Subscribe for More Information
08:05 EDTBMYBristol-Myers says Phase III study evaluating Opdivo stopped early
Subscribe for More Information
07:33 EDTBMYInternational AIDS Society to hold a conference
Subscribe for More Information
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use